Category: Parry
-
Private med reformulator SecureDose acquired by PharmaDrug Inc (PHRX.C)
A few weeks back, in what has become a seminal Equity.Guru piece about the quickly legalizing safe supply drug space, I tore into PharmaDrug (PHRX.C), which was lurching into strategic alternatives land as it appeared to have run out of dough to push its drug trials forward. Pharmadrug (PHRX.C) would love to be in the cocaine…
-
Revive Therapeutics (RVV.C): Covid came, Covid went, but Revive is still fighting
Back at the dawn of Covid-19, a load of public companies started pumping out news releases that claimed they were going to be entering the medical space. In the best tradition of Howe Street, long dormant mining companies suddenly became med-tech deals, hawking everything from clear plastic checkout counter dividers to virus sniffing doorways to…
-
Beacn Wizardry and Magic (BECN.V) unveils new streamer product at TwitchCon 2023
A year ago, when I first talked to the team behind Beacn Wizardry and Magic (BECN.V), nobody paid any attention. Like, literally, nobody. I loved the idea of a local hardware electronics company, run by guys who had fueled the rise of some much larger players with iconic and innovative design, who were looking to…
-
Core Story: Lancaster Resources (LCR.C) opens two fronts on the lithium exploration plan
Lancaster Resources (LCR.C) attracted no attention the first time we mentioned it. “Oh, cool, another lithium project, how original,” barked the usual naysayers in the usual places naysayers say nay. But Penny White has faced down the cynics before, plenty of times (including some we’ve reported on), but she’s not infamous for fading away. Rather,…
-
Core Story: FendX Technologies (FNDX.C) repels and kills pathogens and viruses
We went after this company as a client because there are three things about it that make me swoon. 1: The CEO has done it all before, in this industry, and has more knowledge about her domain than most 2: The product is needed, necessary, cutting edge, and quickly developing with their academic partners 3:…
-
Plurilock Security (PLUR.V) adds new tech patent and extended credit facility
After a month that Plurilock (PLUR.V) shareholders would rather forget stock-price-wise, the big brains at PLUR-HQ have dropped two pieces of news, both of which are substantial in my opinion. The first is, potentially a monster: Plurilock’s snared a patent approval for its core product, which follows a computer user’s rhythms, habits, typing style, and…
-
Buying The Dips: Nextech3D.AI (NTAR.C) hits super-value price – why you should be watching
Listen, we don’t do buy/sell calls at Equity.Guru, because we’re not your financial advisor and we never want to be in a position where we need to apologize for a bad call. When you buy is down to you, your broker, your advisor, your significant other, your less significant other, and your venegeful god of…
-
Multi-Company Wrap: Watching the watchlist so you don’t have to
We have some 29 companies on our watchlist, all in a variety of sectors, that we’re covering at any one time. Some are clients, some not, some are on deaths door, some are skyrocketing, so we’ve decided to wrap them all up into one monthly wrap so you can keep track of everything at once.…
-
Pubco cocaine is here: What does it mean, who’s in, and who’s real?
I recently listened to a podcast episode of Search Engine with PJ Vogt, and I REALLY got into it. The episode was titled, “Why are drug dealers putting fentanyl in everything?” I’d asked myself the same question many times – why kill your customers? I’d recommend you go listen because the answer is a lot…